tirzepatide patent expiration date us Off-patent semaglutide in 2026: the next revolution in anti-obesity medications us7055282 - How do you

2003;284:E931939

Safety findings were consistent with known profiles of both agents, although gastrointestinal adverse events were more common with tirzepatide-containing therapy

Thats not cheap anymore

A placebocontrolled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

Experimental data on animal models have suggested that GIP suppresses peripheral arterial remodeling, thus showing an anti-atherosclerotic activity, by acting on receptors in the heart and vessels." Outcomes of clinical trials The first clinical trial to test the clinical efficacy of TZP was the SURPASS program, a six-stage trial conducted on three separate cohorts Japanese (SURPASS-J), Asian-Pacific (SURPASS-AP), and the cardiovascular outcome trial (SURPASS-CVOT)